Sai Life Sciences Sustainability Report - 2023-24

14 Our Services We provide Discovery and CMC services that span from drug discovery to process development and early-phase supplies, all the way to commercial launch and life cycle management: Discovery: Our Discovery capabilities include standalone and integrated discovery services for innovator pharmaceutical and biotech companies. We have completed discovery programs across therapeutic areas such as oncology, CNS disorders, inflammation, antivirals, rare diseases, among others. The services we offer include: CMC: Our CMC capabilities include the development of scalable chemical manufacturing processes for identified drug candidates and delivering materials for clinical studies as well as commercial sale. Materials supplied include APIs, intermediates, registered starting materials or key starting materials. Discovery Services spanning the entire journey from Target Validation to IND Integrated services: Medicinal Chemistry & Synthetic Chemistry, CADD, Biology, DMPK & Toxicology Target Validation HIT 2 Lead Pre -Clinical HIT ID Chemistry Lead Candidate Toxicology IND Biology In vivo Pharmacology DMPK Phase 1 Phase 2 Phase 3 Process Validation Commercial Supply Lifecycle Strategy Process Chemistry Services from H2L to Commercial Supply Underpinned by integrated scientific approaches applied in a phase-appropriate manner Chemistry & Analytical Toolboxes and Supply Capabi l ity Discovery Process Chemistry API Developability API Developability Commercial Route Selection Process Optimisation & Design Continuous Verification Continuous Improvement Supply Route Optimisation Control Strategy Definition

RkJQdWJsaXNoZXIy MTIwMDc4NQ==